Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Related Questions
How would you manage a patient who developed an intraprostatic abscess after SpaceOAR injection, prior to starting radiation?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
How do you approach rising PSA following radical prostatectomy and early salvage radiation therapy?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
For a patient with a rising PSA after prostatectomy with seminal vesicles being negative for disease at surgery, do you ever treat the prostate bed and seminal vesicle bed with different doses in an SIB plan?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
What are your top takeaways in GU Cancers from ASCO 2025?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
